Pilot Study: Mindfulness-Based Cognitive Therapy as a Tool for Prophylactic Mood Stabilizing Therapy in Bipolar Disorder

NCT ID: NCT00999765

Last Updated: 2023-05-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-06-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the feasibility and short-term efficacy of MBCT as an add-on (i.e. patients must be stable with their regular mood stabilizing medication) for the maintenance therapy of bipolar disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bipolar Disorder - stable

Mindfulness-Based Cognitive Therapy

Intervention Type BEHAVIORAL

eight-week (two hours a week) group therapy (8-12 patients per group)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mindfulness-Based Cognitive Therapy

eight-week (two hours a week) group therapy (8-12 patients per group)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females (\>18 years old)
* Bipolar disorder (as per the Structured Clinical Interview for DSM Disorders (SCID)(22)), euthymic state: Complete remission for at least four weeks ((Montgomery and Asberg Rating Scale (MADRS) ≤ 6 and item-1 (depressed mood) = 0 and no suicidal ideations (MADRS(item-10) \< 4)
* Must have had at least 3 depressive phases in the last 5 years
* Cooperative and willing to complete all the aspects of the study and especially the 45 minutes of exercise per day
* Must have completed a Secondary V (11th grade) education

Exclusion Criteria

* Other active psychiatric disorders (as per the SCID)
* Rapid cycling
* Bipolar disorder secondary to a medical condition or substance-induced mood disorder
* Suicidal ideations (MADRS(item 10)\>3)
* Active i.e. unstable and/or untreated medical condition
* Substance abuse (defined as per DSM-IV) in the last four weeks
* CBT (No more than four sessions (ever))
* Previous participation in a psychoeducation group within the last 6 months
* Current other psychotherapy (more than once a month)
* Practice of meditation (more than once a month) during the last two years
* Practice of yoga (more than once a week) during the last year
* Previous participation in a MBSR group
* Electroconvulsive Therapy (ECT) within the last three months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Douglas Mental Health University Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Serge Beaulieu

Serge Beaulieu

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Serge Beaulieu, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Douglas Mental Health University Institute / McGill

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Douglas Mental Health University Institute

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BD-MBCT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.